DCZ0415, a potent TRIP13 inhibitor, impairs nonhomologous end joining repair and inhibits NF-κB activity. DCZ0415 induces anti-myeloma activity in vitro, in vivo, and in primary cells derived from drug-resistant myeloma patients[1].<br>DCZ0415 (10, 20 μM; 72 hours) shows a significant decrease in colony formation, indicating it inhibits cell proliferation[1].
DCZ0415 (1.25-40 μM; 72 hours) induces a significant dose-dependent decrease of viability in
MM cells[1].
DCZ0415 (10, 20 μM; 24-72 hours) shows a dose-dependent relationship between DCZ0415 treatment and apoptotic cell death[1].
DCZ0415 (10, 20 μM; 24 hours) induces a significant accumulation in G0/G1 MM cells[1].
DCZ0415 (10 μM; 48 hours) decreases the protein levels of phosphorylated (p)-iκBα and phosphorylated (p)-NF-κB in MM cells[1].
DCZ0415 has IC50s of 1.0–10 μM in CalcuSyn in MM cell lines[1].
DCZ0415 exerts cytotoxic effects by inhibiting DNA 288 synthesis in MM cells[1].<br>DCZ0415 (ip; 50 mg/kg/day for 14 days) significantly reduces the growth of MM cells-induced tumors in immune-deficient mice[1].
| Catalog Number | I017385 |
| CAS Number | 2242470-43-3 |
| Molecular Formula | C₂₃H₂₀N₂O₂ |
| Purity | 95% |
| Reference | [1]. Wang Y, et al. A Small Molecule Inhibitor Targeting TRIP13 suppresses multiple myeloma progression. Cancer Res. 2019 Nov 15. pii: canres.3987.2018. |
